Natco pours $17M more into eGenesis, lifting stake to $24.7M
What's the deal? Natco PharmaDealroom has a profile for this one. Try Dealroom → has increased its investment in US-based biotechnology firm eGenesis to $24.70 million, adding $16.70 million through convertible promissory notes. The new commitment, disclosed in September 2026, revises an earlier figure of $14.00 million.
The details: The $16.70 million will flow through two of Natco's wholly owned subsidiaries — NATCO Pharma (Canada) Inc.Dealroom has a profile for this one. Try Dealroom → ($13.70 million) and NATCO Pharma USA LLCDealroom has a profile for this one. Try Dealroom → ($3 million). Both instruments carry an 8% annual interest rate, compounded, and may convert to equity later.
Why now? The disclosure, filed under Regulation 30 of SEBI (LODR) Regulations, 2015, revises an August 25, 2026 intimation. The main changes were a higher investment amount and a switch in the participating subsidiaries. Completion is targeted for October 31, 2026.
What's the endgame? eGenesis is a clinical-stage company using genome engineering to develop transplantable organs, aiming to ease the global shortage of human donors. Its programs cover kidney, liver, and heart transplants. In March 2024, it announced the world's first porcine kidney transplant in a living patient, authorised by the US Food and Drug Administration under the Expanded Access pathway.
The structure: By choosing convertible notes over direct share purchases, Natco secures a fixed return while keeping the option to convert to equity. That lets it fund the target's cash burn without locking in early-stage valuation risk. Natco's relationship with eGenesis dates to 2024, when it first invested $8 million.
The signal: The round ranks near the top for convertible deals in US health, sitting in the 93rd percentile across 801 comparable rounds. For Natco, a generics maker, the deepening stake marks a bet on xenotransplantation as a route to diversify beyond its traditional business.
Read more: scanx.trade
Image credit: Generated with Gemini
